Huntington disease is a fatal neurodegenerative disorder caused by expansion of a polyglutamine tract in the protein huntingtin (Htt) 1 , which leads to its aggregation in nuclear and cytoplasmic inclusion bodies 2 . We recently identified 52 loss-of-function mutations in yeast genes that enhance the toxicity of a mutant Htt fragment 3 . Here we report the results from a genome-wide loss-of-function suppressor screen in which we identified 28 gene deletions that suppress toxicity of a mutant Htt fragment. The suppressors are known or predicted to have roles in vesicle transport, vacuolar degradation, transcription and prion-like aggregation. Among the most potent suppressors was Bna4 (kynurenine 3-monooxygenase), an enzyme in the kynurenine pathway of tryptophan degradation that has been linked directly to the pathophysiology of Huntington disease in humans by a mechanism that may involve reactive oxygen species 4 . This finding is suggestive of a conserved mechanism of polyglutamine toxicity from yeast to humans and identifies new candidate therapeutic targets for the treatment of Huntington disease.
Expression of a mutant Htt fragment (Htt103Q) 5 in yeast, as in neurons, results in the formation of inclusion bodies and confers cellular toxicity (Fig. 1) . We carried out a loss-of-function (LOF) screen with a library of Saccharomyces cerevisiae strains (Supplementary Note online) to identify gene deletions that suppress Htt103Q-induced toxicity and identified 28 suppressors in 4,850 strains ( Table 1 and Fig. 1a ) that expressed Htt103Q at similar levels to the parental strain ( Supplementary Fig. 1 online) . Htt103Q formed inclusion bodies in most of the LOF suppressor strains (Fig. 1b) , consistent with previous studies indicating that inclusion body formation by mutant Htt fragments is not sufficient for toxicity and may instead be a protective mechanism 6, 7 . Of the LOF suppressors isolated, B86% (24 of 28) correspond to genes with known or predicted functions. Recent work has implicated the cellular process of autophagy in the pathology of Huntington disease [8] [9] [10] . Autophagy in yeast occurs in the vacuole, the functional equivalent of the mammalian lysosome. Of the suppressors isolated in our screen with known or predicted functions, 25% (6 of 24) encode proteins that cluster into the functionally related categories of vesicular transport, vacuolar protein sorting and vacuolar import (Bfr1, Cyk3, Def1, Mso1, Sna2 and Vps53). Because many of these gene deletion strains show perturbation of protein sorting to the vacuole, we hypothesize that abnormal sorting of Htt103Q relieves toxicity.
Transcriptional dysregulation may be important in Huntington disease pathogenesis 11 . It is not unexpected that B25% (6 of 24) of the suppressors identified in our screen encode proteins that are involved directly in transcription or in establishment or maintenance of chromatin architecture (Mbf1, Nhp6b, Paf1, Rxt3, Ume1 and Ylr278c). Two of these proteins, Ume1 and Rxt3, are members of the yeast Rpd3 histone deacetylase (HDAC) complex. Pharmacological and genetic inhibition of the functionally equivalent HDAC complex in Drosophila melanogaster ameliorates neurodegeneration and viability in models of polyglutamine (polyQ) disease 12 , and pharmacological inhibition of HDAC activity improves motor deficits in a mouse model of Huntington disease 13, 14 . Ume1 is required for full transcriptional repression of a subset of genes in yeast, in a mechanism that requires Rpd3 (ref. 15) , suggesting that genetic inhibition of the yeast Rpd3 HDAC complex relieves polyQ toxicity in a mechanism similar to that observed in fly and mouse models of polyQ disease. The simplest interpretation of these results is that putative transcriptional abnormalities induced by Htt103Q are correlated to toxicity, and that transcriptional dysfunction is ameliorated by the suppressor mutations.
Approximately 21% (5 of 24) of the suppressor genes encode known yeast prions (Rnq1) or proteins containing Gln/Asn-rich regions that may mediate prion-like aggregation (Def1, Ybr016w, Yir003w and Ylr278c) 16 . Rnq1 in its prion conformation is necessary for Htt103Q-mediated toxicity 5 ; analysis of several of the suppressor strains confirmed that Rnq1 remained in its prion conformation when expression of Htt103Q was induced ( Supplementary Fig. 1 online) . The finding that a network of putative prion-like proteins is required for Htt103Q-mediated toxicity in yeast is new and suggests that yeast prions may have evolved to modulate aggregation or the biological functions of Gln/Asn-rich proteins.
Among the most potent LOF suppressor mutations identified in our screen was a gene that encodes Bna4 (kynurenine 3-monooxygenase, KMO). This mitochondrial enzyme is notable because it functions in the kynurenine pathway, which is activated in individuals with Huntington disease and in animal models of Huntington disease 4 . The kynurenine pathway is the main route of tryptophan degradation in eukaryotes and leads to synthesis of NAD + (Fig. 2a) . Intrastriatal injection of the kynurenine pathway metabolite quinolinic acid (QUIN) in rodents reproduces behavioral and pathological features of Huntington disease 17 , raising the possibility that alterations in QUIN metabolism may be central to Huntington disease pathophysiology 4 . Endogenous levels of QUIN, which is synthesized by the cerebral kynurenine pathway, are elevated in the neostriatum and in the cortex of individuals with early stage (grade 0 and 1) Huntington disease 18 . This pathway also includes 3-hydroxykynurenine (3HK), which potentiates QUIN neurotoxicity 19 and is elevated preferentially in the neostriatum and cortex of individuals with stage 1 Huntington disease and in mice expressing mutant Htt 20 . It is, therefore, notable that deletion of BNA4, predicted to eliminate production of both 3HK and QUIN in yeast, strongly suppressed Htt103Q-mediated toxicity (Fig. 2b) .
Because the enzymes and metabolites involved in the kynurenine pathway are well conserved between yeast and humans ( Fig. 2a) , we assayed cell viability of gene deletion strains for all the enzymes involved in this pathway when expressing Htt103Q (Fig. 2b) . In addition, we characterized levels of 3HK and QUIN in several of these strains. As predicted from studies in humans and mice, 3HK Fig. 3a) . Levels of QUIN also increased significantly (P o 0.001) in cells expressing Htt103Q (Fig. 3a) . As predicted, no 3HK or QUIN was detected in cells lacking Bna4 (Fig. 3a) .
The enzyme encoded by BNA1, 3-hydroxyanthranilate 3,4-dioxygenase, functions downstream of KMO and catalyzes the final enzyme-dependent step of the kynurenine pathway upstream of QUIN (Fig. 2a) . Therefore, deletion of BNA1 is predicted to eliminate production of QUIN and result in increased levels of 3HK. Levels of 3HK were significantly higher in bna1D cells expressing Htt103Q than in either the parental strain or bna1D cells carrying an empty vector (P o 0.001 and P o 0.01, respectively), whereas QUIN was undetectable (Fig. 3a) . Deletion of BNA1 partially suppressed Htt103Q-mediated toxicity (Fig. 2b) , consistent with an additive effect of QUIN and 3HK in Htt103Q-mediated toxicity.
Deletion of two kynurenine pathway genes, ARO9 and NPT1, enhanced Htt103Q toxicity (Fig. 2b) . Deletion of ARO9 blocks synthesis of kynurenic acid from kynurenine, probably increasing levels of kynurenine and downstream metabolites. In addition, kynurenic acid may be protective owing to its activity as a free-radical scavenger 21 . Deletion of NPT1 blocks synthesis of NAD + from nicotinic acid, forcing all synthesis of NAD + to occur through the kynurenine pathway and probably causing upregulation of the pathway. Consistent with the enhancement of Htt103Q toxicity observed in aro9D and npt1D cells, levels of 3HK were 90 and 15 times higher (P o 0.001), respectively, and levels of QUIN were 10 times higher in npt1D cells (P o 0.001) in comparison to the parental strain that expressed Htt103Q (Fig. 3b) . Levels of 3HK were also elevated in aro9D cells carrying empty vector compared with the parental strain, but expression of Htt103Q increased levels of 3HK by a factor of 440 (P o 0.001; Fig. 3b ). The remaining kynurenine pathway gene deletions did not have a detectable effect on Htt103Q-mediated toxicity. Ro 61-8048, a high-affinity small-molecule inhibitor of KMO (the mammalian ortholog of Bna4) 22 , is neuroprotective in models of brain ischemia 23 and in a genetic model of paroxysmal dyskinesia 24 . We next explored whether pharmacological inhibition of Bna4 by Ro 61-8048 could reduce levels of 3HK and QUIN in yeast and thereby suppress Htt103Q-dependent toxicity. Treatment of yeast cells expressing Htt103Q with Ro 61-8048 reduced levels of 3HK to nearly wildtype levels (Fig. 3c) . But levels of the downstream metabolite QUIN were unaffected by treatment with Ro 61-8048, indicating that Ro 61-8048 only partially inhibits Bna4 activity in yeast. Consistent with this result, treatment of yeast cells expressing Htt103Q with Ro 61-8048 conferred a partial, but significant, improvement in growth that was dose-dependent (Fig. 3d) .
How might kynurenines induce toxicity in cells that express mutant Htt? The neurotoxin 3HK is present in the brain in nanomolar concentrations, but at higher levels can kill neurons by generating toxic free radicals that initiate a cascade of events leading to cell death 25 . Toxicity of QUIN, on the other hand, is proposed to be due to a combination of factors: activation of N-methyl-D-aspartate (NMDA) receptors and generation of toxic free radicals 25 . The common ability of 3HK and QUIN to generate toxic free radicals led us to analyze levels of reactive oxygen species (ROS) by fluorescence microscopy in yeast cells in the absence and presence of Htt103Q (Fig. 4a) . Levels of ROS were B8 times higher (P ¼ 0.001) in cells expressing Htt103Q versus Htt25Q but were not significantly different in bna4D cells expressing Htt103Q versus Htt25Q (P ¼ 0.4; Fig. 4a,b) . In addition, treatment of cells expressing Htt103Q with Ro 61-8048 reduced levels of ROS significantly (P ¼ 0.011; Fig. 4c ). Taken together, these data show that genetic or pharmacological reduction of KMO activity ameliorates increases in ROS in yeast expressing Htt103Q. This supports observations in neuronal cells and mice showing increases in ROS with expression of mutant Htt 26, 27 and suggests that increased ROS levels in yeast cells expressing Htt103Q are probably due to abnormally high levels of 3HK and QUIN.
These results suggest that a conserved mechanism of polyQ toxicity exists in yeast and individuals with Huntington disease involving upregulation of the kynurenine pathway metabolites 3HK and QUIN leading to generation of ROS. Because most brain kynurenines are synthesized in astrocytes and microglia 25 and microglia are activated in individuals with Huntington disease 28 and by intrastriatal injection of QUIN in rats 29 , our results suggest that some of the effects of mutant Htt may not be cell-autonomous and may involve cells other than neurons. Secretion of cytokines by dysfunctional neurons expressing mutant Htt may lead to the local activation of microglia, causing 3HK and QUIN production, and this in turn may contribute to neurodegeneration observed in Huntington disease 25 . In an alternative but not mutually exclusive model, we propose here that expression of mutant Htt in astrocytes and microglia leads directly to cellular dysfunction in these cells, thereby resulting in elevated 3HK and QUIN production (Fig. 5) .
Inhibition of the kynurenine pathway by genetic or pharmacological means has a substantial effect on polyQ-mediated toxicity, 3HK and QUIN production, and generation of ROS in yeast expressing Htt103Q. A recent high-throughput screen of 16,000 small chemical compounds in yeast expressing Htt103 identified a single drug that suppressed neurodegeneration in a fly model of polyQ disease 30 . This compound is a structural analog of the KMO inhibitor Ro 61-8048, providing further support for the idea that pharmacological inhibition of KMO may ameliorate mutant Htt-mediated toxicity. Our data suggest that KMO, and perhaps other enzymes of the kynurenine pathway, are good candidates for drug development. Preclinical trials with Ro 61-8048 are currently underway using mouse models of Huntington disease. Finally, the results from this and our previous genetic screen 3 may help guide future efforts in cellular and animal models to elucidate the genetic pathways and molecular mechanisms underlying neurodegeneration in Huntington disease.
METHODS
Yeast genomic screen for LOF suppressors of Htt103Q-mediated toxicity. We obtained the yeast gene deletion set, a collection of 4,850 yeast MATa (BY4741) haploid deletion strains, frozen in glycerol stocks in 96-well microtiter dishes from Research Genetics. We grouped these strains into four pools of B1,200 strains as previously described 3 . We transformed the deletion set with pYES2-Htt103Q-GFP 5 using the lithium acetate method. Htt103Q is a galactose (GAL)-inducible, FLAG-and GFP-tagged construct encoding the first 17 amino acids of Htt fused to a polyQ tract of 103 glutamines, longer than the threshold for Huntington disease pathogenesis. We screened each pool to B12-fold coverage by selection on plates containing synthetic complete media lacking uracil (SC ÀUra) for a combined total of B6.0 Â 10 4 individual transformants. We estimated the total number of transformants on a control plate containing glucose (GLU) as the sole carbon source (SC ÀUra +GLU). We selected LOF suppressors of Htt103Q toxicity on plates containing GAL as the sole carbon source (SC ÀUra +GAL). The presence of GAL induces the expression of Htt103Q under control of the GAL1 promoter. We analyzed plates after 3 d of incubation at 30 1C and selected colonies that grew on the SC ÀUra +GAL plates for further analysis. We subjected 366 colonies to preliminary retesting by streaking them onto a SC ÀUra +GAL master plate. We selected transformants that retained the ability to grow on plates containing GAL for further testing.
Identification and retesting of suppressors. We used colony PCR analysis to amplify a 20-bp barcode sequence that uniquely identified each deletion strain for all of the 366 suppressors isolated in the screen. We sequenced the PCR product using standard DNA sequencing methods and used the barcode sequence as a query in a BLAST search of the yeast gene deletion set database (Saccharomyces Genome Deletion Project), identifying the deletion strain. Because we isolated many gene deletions numerous times, the 366 suppressors defined a total of 167 individual gene deletions. We streaked all the identified suppressor strains freshly from the original frozen stocks of the yeast gene deletion set and retransformed them with the pYES2-Htt103Q construct for subsequent analysis. We retested all transformed deletion strains for suppression of Htt103Q-mediated toxicity using spotting assays to ensure that suppression of toxicity was not due to second-site mutations. We did not observe any strong growth defects among the strains being tested that might have affected interpretation of the suppression analysis. We kept B18% (30 of 67) of the putative suppressors retested for suppression of toxicity for further analysis.
We identified mammalian homologs of yeast genes using annotations from the Incyte Proteome BioKnowledge Library. In the proteome library, protein sequences are aligned with Gapped BLAST (v2.0.10) with SEG and COIL filtering; alignments with an expectation score of r1 Â 10 À3 are refined by Smith-Waterman alignment algorithms from the USC Sequence alignment package v2.0, with no filtering. In this study, we identified homologs for yeast proteins without known functional orthologs by selection from related proteins with an expectation score of r1 Â 10 À4 and match lengths of 450% of the full-length sequence of the homologous protein. Brain expression data were based on cDNA expression profiles at Unigene database.
Microscopy. We acquired fluorescent images using a Deltavision deconvolution microscope with 40Â or 100Â oil immersion objectives. We grew 1-to 2-ml yeast cultures to log phase (A 600 ¼ 0.5-0.9) in SC ÀUra +GAL or SC ÀUra +GLU medium for 2 d. We then centrifuged the cultures at 10,000g for 2 min, removed the medium and resuspended the pellet in 100 ml of phosphatebuffered saline. We pipetted 1 ml of the resuspension onto a pad of 5% agarose on a microscope slide and sealed it with a cover slip. To examine GFP fluorescence, we exposed cells to light of wavelength 490 nm and viewed them through a 528 +/À 38 nm filter. To examine ROS using DHE (Molecular Probes), we grew yeast to log phase in 1-to 2-ml cultures in SC ÀUra +GAL or SC ÀUra +GLU medium. DHE is oxidized to ethidium by superoxide anions, and the production of ROS is visualized by an increase in ethidium staining of DNA. We centrifuged cultures at 10,000g for 2 min and then resuspended the pellet in 100 ml of phosphate-buffered saline. We added DHE at a concentration of 5 mM and incubated the cells with shaking for 30 min at 30 1C. We centrifuged the cells, removed the medium and resuspended the pellet in 100 ml of phosphate-buffered saline. We added 1 ml of cells to a microscope slide with a 5% agarose pad. We quantified ROS using the dye DHR (Molecular Probes). DHR passively diffuses across cell membranes, where it is oxidized to cationic rhodamine 123. To visualize DHR, we exposed cells to light of wavelength 555 nm and viewed them through a 617 +/À 73 nm filter. Experiments were done in triplicate with B300 cells per sample. Experiments with DHR were done using Htt25Q and Htt103Q tagged with RFP. Ro 61-8048 treatment was done in the pleiotropic drug response deletion strain pdr1Dpdr3D in the W303 strain background. The no-drug control was done with 1% dimethylsulfoxide. All images were acquired and deconvolved using Softworx (Applied Precision) with an Olympus 1X-HLS100 camera.
Biochemical analysis. We prepared yeast extracts as described above, except we substituted ultrapure water for lysis buffer. We added 6% perchloric acid at a ratio of 1:5 and separated the precipitated protein by centrifugation. We determined levels of both 3HK and QUIN from the same yeast extracts in triplicate using high-performance liquid chromatography and gas chromatography-mass spectrometry analyses as described previously 18 . Growth curves. We started growth curves by diluting overnight SC ÀUra raffinose cultures to A 600 ¼ 0.2 and then induced expression of Htt103Q by adding a final concentration of 2% GAL. We measured absorbance at 600 nm on an Ultrospec 2100 Pro spectrophotometer over a period of 16.5 h. We added drug (Ro 61-8048, 1 mM or 100 mM in 1% dimethylsulfoxide) or 1% dimethylsulfoxide to the appropriate samples coincidentally with GAL induction. Drug testing was done in the drug-permeable strain erg6D in the BY4741 parental background.
